1. Vaccines for COVID-19: Where do we stand in 2021?
- Author
-
Archana Koirala, Philip N Britton, Clayton Chiu, Katrina Nicolopoulos, Nicholas Wood, and Ketaki Sharma
- Subjects
Pulmonary and Respiratory Medicine ,COVID-19 Vaccines ,Special populations ,Adolescent ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Distribution (economics) ,Environmental health ,Humans ,Medicine ,Child ,Drug Approval ,Pandemics ,11 Medical and Health Sciences ,Vaccines ,SARS-CoV-2 ,business.industry ,COVID-19 ,Coronavirus ,Clinical trial ,Vaccination ,1107 Immunology ,Pediatrics, Perinatology and Child Health ,Observational study ,Mini-symposium: COVID 19: The second year ,business ,High income countries - Abstract
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARS-CoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. more...
- Published
- 2021
- Full Text
- View/download PDF